Referências:
LBA500:
Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant
treatment in patients with HR+/HER2− early breast cancer.
LBA506: 3-year invasive disease-free
survival (iDFS) of the strategy-based, randomized phase II PHERGain trial
evaluating chemotherapy (CT) de-escalation in human epidermal growth factor
receptor 2-positive (HER2[+]) early breast cancer (EBC).
--
